Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00338936 |
This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients. The 350 patients (approximately) who have successfully finished the core trial CVAH631B1303 and signed consent for the extension will be enrolled into this study.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Valsartan + Hydrochlorothiazide |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A 52-Week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) - |
Estimated Enrollment: | 350 |
Study Start Date: | May 2006 |
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CVAH631B1303E1 |
Study First Received: | June 16, 2006 |
Last Updated: | October 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00338936 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Hypertension Valsartan Hydrochlorothiazide |
Vascular Diseases Essential hypertension Hydrochlorothiazide Valsartan Hypertension |
Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Natriuretic Agents Therapeutic Uses Sodium Chloride Symporter Inhibitors Physiological Effects of Drugs |
Diuretics Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |